<p>Kezar Life Sciences, Inc.（纳斯达克代码：KZR - 获取免费报告）的股票在目前覆盖该股票的六位分析师中获得了 “减持” 的共识评级，MarketBeat 报道。两位股票研究分析师给予该股票卖出建议，四位分析师则对该公司给予持有建议。在过去一年中，发布报告的券商对该股票的平均一年目标价为 6.00 美元。</p>
<p>获取 <strong>Kezar Life Sciences</strong> 的提醒：</p>
<h2>Kezar Life Sciences 股票表现</h2>
<p>纳斯达克 KZR 的股票周二开盘价为 7.39 美元。该公司的市值为 5446 万美元，市盈率为-0.96，贝塔系数为 0.40。Kezar Life Sciences 的 52 周低点为 3.53 美元，52 周高点为 7.55 美元。该公司的 50 日移动平均线为 7.06 美元，200 日移动平均线为 6.49 美元。</p>
<p>Kezar Life Sciences（纳斯达克代码：KZR - 获取免费报告）最近于 3 月 27 日星期五发布了季度财报。该公司报告季度每股收益（EPS）为（1.99 美元），低于共识预期的（1.39 美元）0.60 美元。分析师预计 Kezar Life Sciences 在当前财政年度将发布-2.24 美元的每股收益。</p>
<h2>对 Kezar Life Sciences 的对冲基金看法</h2>
<p>机构投资者最近增加或减少了对该公司的持股。Nantahala Capital Management LLC 在第四季度购买了 Kezar Life Sciences 的新股份，价值约为 1,741,000 美元。Affinity Asset Advisors LLC 在第四季度购买了 Kezar Life Sciences 的股份，价值约为 1,441,000 美元。BML Capital Management LLC 在第三季度将其在 Kezar Life Sciences 的持股增加了 13.5%。BML Capital Management LLC 目前拥有 720,787 股该公司的股票，价值 2,811,000 美元，此前在上个季度额外购买了 85,604 股。Aldebaran Capital LLC 在第四季度购买了 Kezar Life Sciences 的新股份，价值为 507,000 美元。最后，Credit Industriel ET Commercial 在第一季度购买了 Kezar Life Sciences 的新股份，价值为 398,000 美元。对冲基金和其他机构投资者持有该公司 67.90% 的股票。</p>
<h2>关于 Kezar Life Sciences</h2>
<p>（获取免费报告）</p>
<p>Kezar Life Sciences 是一家临床阶段的生物技术公司，专注于发现和开发调节先天免疫系统的新型小分子疗法。该公司的研究集中在选择性抑制免疫蛋白酶体，这是一个参与抗原处理和炎症细胞因子分泌的关键蛋白复合物。通过针对这一途径，Kezar 旨在以高特异性和良好的安全性解决自身免疫和炎症疾病中的未满足医疗需求。</p>
<p>该公司的主要开发候选药物 KZR-616 是一种选择性免疫蛋白酶体抑制剂，目前正在多个临床试验中评估用于系统性红斑狼疮、狼疮性肾炎、多发性肌炎和皮肌炎等自身免疫疾病。</p>
<h2>相关文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Kezar Life Sciences</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1pS?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1pS"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Kezar Life Sciences 吗？</h2>
<p>在你考虑 Kezar Life Sciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Kezar Life Sciences 并不在名单上。</p>
<p>虽然 Kezar Life Sciences 目前在分析师中获得减持评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

基因改革 ETF - ARK

纽交所高增长板生物技术指数 ETF - First Trust

<p>Kezar Life Sciences, Inc.（纳斯达克代码：KZR）获得了六位分析师的共识评级为 “减持”，其中两位建议卖出，四位建议持有。平均一年期目标价为 6.00 美元。该股票开盘价为 7.39 美元，市值为 5446 万美元。公司报告的季度每股收益为（1.99 美元），未达到预期。机构投资者持有 67.90% 的股份。Kezar 专注于开发自身免疫疾病的治疗方案，其主要候选药物 KZR-616 正在进行临床试验</p>

<p>Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR - Get Free Report) have earned a consensus rating of &#34;Reduce&#34; from the six analysts that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $6.00.</p>
<div class="lb-trans"><p>Kezar Life Sciences, Inc.（纳斯达克代码：KZR - 获取免费报告）的股票在目前覆盖该股票的六位分析师中获得了 “减持” 的共识评级，MarketBeat 报道。两位股票研究分析师给予该股票卖出建议，四位分析师则对该公司给予持有建议。在过去一年中，发布报告的券商对该股票的平均一年目标价为 6.00 美元。</p>
</div><p>Get <strong>Kezar Life Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Kezar Life Sciences</strong> 的提醒：</p>
</div><h2>Kezar Life Sciences Stock Performance</h2>
<div class="lb-trans"><h2>Kezar Life Sciences 股票表现</h2>
</div><p>Shares of NASDAQ KZR opened at $7.39 on Tuesday. The company has a market cap of $54.46 million, a P/E ratio of -0.96 and a beta of 0.40. Kezar Life Sciences has a 52-week low of $3.53 and a 52-week high of $7.55. The firm's fifty day moving average is $7.06 and its two-hundred day moving average is $6.49.</p>
<div class="lb-trans"><p>纳斯达克 KZR 的股票周二开盘价为 7.39 美元。该公司的市值为 5446 万美元，市盈率为-0.96，贝塔系数为 0.40。Kezar Life Sciences 的 52 周低点为 3.53 美元，52 周高点为 7.55 美元。该公司的 50 日移动平均线为 7.06 美元，200 日移动平均线为 6.49 美元。</p>
</div><p>Kezar Life Sciences (NASDAQ:KZR - Get Free Report) last released its quarterly earnings data on Friday, March 27th. The company reported ($1.99) EPS for the quarter, missing the consensus estimate of ($1.39) by ($0.60). As a group, analysts forecast that Kezar Life Sciences will post -2.24 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Kezar Life Sciences（纳斯达克代码：KZR - 获取免费报告）最近于 3 月 27 日星期五发布了季度财报。该公司报告季度每股收益（EPS）为（1.99 美元），低于共识预期的（1.39 美元）0.60 美元。分析师预计 Kezar Life Sciences 在当前财政年度将发布-2.24 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Kezar Life Sciences</h2>
<div class="lb-trans"><h2>对 Kezar Life Sciences 的对冲基金看法</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC bought a new stake in Kezar Life Sciences in the 4th quarter worth approximately $1,741,000. Affinity Asset Advisors LLC bought a new position in shares of Kezar Life Sciences during the 4th quarter valued at approximately $1,441,000. BML Capital Management LLC boosted its position in shares of Kezar Life Sciences by 13.5% during the 3rd quarter. BML Capital Management LLC now owns 720,787 shares of the company's stock valued at $2,811,000 after acquiring an additional 85,604 shares during the last quarter. Aldebaran Capital LLC purchased a new position in shares of Kezar Life Sciences in the fourth quarter valued at $507,000. Finally, Credit Industriel ET Commercial purchased a new position in shares of Kezar Life Sciences in the first quarter valued at $398,000. Hedge funds and other institutional investors own 67.90% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对该公司的持股。Nantahala Capital Management LLC 在第四季度购买了 Kezar Life Sciences 的新股份，价值约为 1,741,000 美元。Affinity Asset Advisors LLC 在第四季度购买了 Kezar Life Sciences 的股份，价值约为 1,441,000 美元。BML Capital Management LLC 在第三季度将其在 Kezar Life Sciences 的持股增加了 13.5%。BML Capital Management LLC 目前拥有 720,787 股该公司的股票，价值 2,811,000 美元，此前在上个季度额外购买了 85,604 股。Aldebaran Capital LLC 在第四季度购买了 Kezar Life Sciences 的新股份，价值为 507,000 美元。最后，Credit Industriel ET Commercial 在第一季度购买了 Kezar Life Sciences 的新股份，价值为 398,000 美元。对冲基金和其他机构投资者持有该公司 67.90% 的股票。</p>
</div><h2>About Kezar Life Sciences</h2>
<div class="lb-trans"><h2>关于 Kezar Life Sciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company's research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.</p>
<div class="lb-trans"><p>Kezar Life Sciences 是一家临床阶段的生物技术公司，专注于发现和开发调节先天免疫系统的新型小分子疗法。该公司的研究集中在选择性抑制免疫蛋白酶体，这是一个参与抗原处理和炎症细胞因子分泌的关键蛋白复合物。通过针对这一途径，Kezar 旨在以高特异性和良好的安全性解决自身免疫和炎症疾病中的未满足医疗需求。</p>
</div><p>The company's lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.</p>
<div class="lb-trans"><p>该公司的主要开发候选药物 KZR-616 是一种选择性免疫蛋白酶体抑制剂，目前正在多个临床试验中评估用于系统性红斑狼疮、狼疮性肾炎、多发性肌炎和皮肌炎等自身免疫疾病。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than Kezar Life Sciences</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Kezar Life Sciences</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1pS" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=KZR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kezar Life Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Kezar Life Sciences 吗？</h2>
</div><p>Before you consider Kezar Life Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Kezar Life Sciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kezar Life Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Kezar Life Sciences 并不在名单上。</p>
</div><p>While Kezar Life Sciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kezar Life Sciences 目前在分析师中获得减持评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of "Reduce" by Analysts

Market Beat

Kezar Life Sciences

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

美国制药 ETF - iShares

医药突破 ETF - ALPS

标普生物技术 3 倍做多 - Direxion

医疗业 ETF - Vanguard

标普全球医疗股指数 ETF - iShares

医疗业 ETF - SPDR

Kezar Life Sciences, Inc.（纳斯达克股票代码：KZR）被分析师一致建议为 “减持”